Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
| ▸ | FPR1 | P21462 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23426122 | 0.87 | SAE1 (0.41) | NPC1RAB9ASMN1; SMN2KLKB1KLK1 | |
| SCHEMBL23426162 | 0.77 | LTA4H (0.40) | KDM4EBRD4TSHR | |
| SCHEMBL19355326 | 0.75 | NPBWR1 (0.42) | POLBL3MBTL1 | |
| SCHEMBL15342931 | 0.75 | PKM (0.50) | POLBSMN1; SMN2GAAMAPT | |
| SCHEMBL18329643 | 0.73 | GAA (0.40) | NPC1RAB9AKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL21297544 | 0.71 | MTNR1A (0.42) | KMT2ASMN1; SMN2L3MBTL1KDM4EGAA | |
| SCHEMBL18056104 | 0.70 | PDE1B (0.51) | POLB | |
| SCHEMBL4789449 | 0.69 | PDE1B (0.46) | NPC1RAB9APOLBSMN1; SMN2KDM4E | |
| SCHEMBL15328821 | 0.68 | GSK3A (0.41) | NPC1RAB9APOLB | |
| SCHEMBL29600977 | 0.68 | MAOB (0.58) | NPC1SMN1; SMN2KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160368899-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368899-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | NPC1 627/4885RAB9A 4213/4885POLB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.